体外膜肺氧合模式对重症患者伏立康唑暴露的影响
该回顾性观察研究纳入2018年1月至2025年5月ICU中因疑似真菌感染使用伏立康唑的166例患者(492份样本),比较ECMO与非ECMO患者的伏立康唑谷浓度(Cmin)。总体ECMO与非ECMO组Cmin无显著差异,但VAV-ECMO组Cmin显著低于非ECMO组(P=0.004),VV-ECMO和VA-ECMO与非ECMO相当。年龄增加和合用胺碘酮与Cmin升高相关,低白蛋白和合并CRRT与Cmin降低相关。
要点
- ECMO整体不显著降低伏立康唑Cmin,但VAV-ECMO模式与Cmin降低相关。
- 年龄增加和合用胺碘酮与伏立康唑Cmin升高相关。
- 低白蛋白水平和合并CRRT与伏立康唑Cmin降低相关。
核心结论
- ECMO支持整体未显著降低伏立康唑Cmin,但VAV-ECMO与伏立康唑暴露降低相关,提示ECMO效应具有模式特异性而非统一效应。
研究设计与样本
- 回顾性观察研究,纳入2018年1月至2025年5月ICU中因疑似真菌感染使用伏立康唑的患者166例(492份样本),其中ECMO组33例(111份样本),非ECMO组133例(381份样本)。
主要发现
- ECMO组与非ECMO组伏立康唑谷浓度无显著差异。
- 按模式分层,VAV-ECMO组浓度显著低于非ECMO组(P=0.004),VV-ECMO和VA-ECMO与非ECMO相当。
- 多因素线性回归显示年龄增加和合用胺碘酮与伏立康唑Cmin升高相关。
- 低白蛋白水平和合并CRRT与伏立康唑Cmin降低相关。
临床怎么用
- ECMO患者尤其是VAV-ECMO模式患者应常规进行伏立康唑治疗药物监测。
- 关注年龄、白蛋白水平、合用胺碘酮及CRRT对伏立康唑Cmin的影响。
局限性
- 回顾性观察设计。
- ECMO组样本量较小(33例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Voriconazole is widely used for invasive fungal infections in critically ill patients, but its pharmacokinetics may be significantly altered by extracorporeal membrane oxygenation (ECMO). Data on the impact of different ECMO modes are limited. METHODS: We performed a retrospective observational study including all patients admitted to the ICU from January 2018 to May 2025 who were treated with voriconazole for suspected fungal infections. Voriconazole trough concentrations (Cmin) were compared between ECMO and non-ECMO patients. Multivariate linear regression was used to identify clinical predictors of Cmin, and subgroup analyses were performed by ECMO mode and other relevant covariates. RESULTS: A total of 166 patients (492 samples) were included, including 33 ECMO patients (111 samples) and 133 non-ECMO patients (381 samples). There was no significant difference in voriconazole trough concentrations between the ECMO and non-ECMO groups. When stratified by mode, VAV-ECMO was associated with significantly lower concentrations than non-ECMO (P = 0.004), whereas VV- and VA-ECMO were comparable to non-ECMO. In multivariate linear regression, increasing age and coadministration with amiodarone were associated with higher voriconazole Cmin, whereas lower albumin levels and concomitant CRRT were associated with reduced concentrations. CONCLUSIONS: ECMO support did not significantly reduce voriconazole Cmin compared with the non-ECMO group. However, VAV-ECMO is associated with reduced voriconazole exposure, suggesting a configuration-specific rather than uniform ECMO effect. Routine therapeutic drug monitoring remains essential.
引用
- Wang X, Zhang H, Song S, et al. Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients. J Antimicrob Chemother. 2026. PMID: 41549655. doi:10.1093/jac/dkaf501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。